<DOC>
	<DOCNO>NCT01843400</DOCNO>
	<brief_summary>This study regulatory post-marketing surveillance Japan , local prospective observational study patient receive Regorafenib colorectal cancer . The objective study ass safety effectiveness Regorafenib use real clinical practice . A total 1,250 patient enrol assessed 6 month standard observational period . At 12 month first administration Regorafenib confirmation efficacy information include treatment duration survival status patient .</brief_summary>
	<brief_title>Regorafenib Post-marketing Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients determine start Regorafenib/ STIVARGA treatment Patients previously receive Regorafenib/ STIVARGA</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>Colorectal Neoplasms</keyword>
</DOC>